AstraZeneca and Bristol Myers Squibb in talks for a $400 billion merger
AstraZeneca and Bristol Myers Squibb are exploring a merger valued at $400 billion.
Published 14sem6 sources✓ ConfirmedImportantupdated 13sem
Lire en français
≈ 16s
The fact
AstraZeneca's shares dropped nearly 7% following the announcement.
This merger would create a global pharmaceutical giant.
6 sources — click a link to read an article on the topic: